To validate that loss of CBFβ confers tumour cell resistance to CAR-T cell killing, we depleted CBFβ in MC38-HER2 tumour cells by electroporating cells with a CRISPR/Cas9-sgCbfb ribonucleoprotein (RNP) complex (Fig. 1F). The gene discussed is CBFB; the disease is neoplasm.